for Anti-Flu Virus Drug Oseltamivir Phosphate CAS 204255-11-8 Powder

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: HB- Oseltamivir Phosphate
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• MOQ: 1kg
• Assay: 99%
• Sample: Availiable
• Shipping Method: FedEx, DHL, TNT, EMS
• Stock: in Stock
• Delivery Time: 5-7days
• Appearance: White Powder
• Storage: Cool Dry Place
• CAS: 204255-11-8
• Shelf Life: 2 Years
• Product Name: Oseltamivir Phosphate
• Mf: C16h31n2o8p
• Einecs: 616-396-9
• Transport Package: Aluminum Foil Bag
• Specification: 1kg/ bag, 25kg/ barrel
• Trademark: Herben
• Origin: China, Shaanxi
• Production Capacity: 100000

Product Description

  For Anti-Flu Virus Drug Oseltamivir Phosphate CAS 204255-11-8 Powder

 

 

Product name	Oseltamivir Phosphate
CAS No.	204255-11-8
Molecular formula	C16H31N2O8P
Molecular weight	410.4
Purity	99%
Appearance	White or almost white powder
Package	Aluminum Bag;Drums
Shelf life	2 years

 
Oseltamivir, sold under the brand name Tamiflu, is an antiviral medication used to treat and prevent influenza A and influenza B
(flu).Many medical organizations recommend it in people who have complications or are at high risk of complications within 48
hours of first symptoms of infection.They recommend it to prevent infection in those at high-risk, but not the general population.
The CDC recommends that clinicians use their discretion to treat those at lower risk who present within 48 hours of first symptoms
of infection.It is taken by mouth, either as a pill or liquid.

Oseltamivir is used for the prevention and treatment of influenza caused by influenza A and B viruses.It is on the World Health
Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.Oseltamivir's
risk-benefit ratio is controversial.

High risk people
The United States' Centers for Disease Control and Prevention (CDC), European Centre for Disease Prevention and Control (ECDC),
Public Health England and the American Academy of Pediatrics (AAP) recommend the use of oseltamivir for people who have
complications or are at high risk for complications.This includes those who are hospitalized, young children, those over the age
of 65, people with other significant health problems, those who are pregnant, and Indigenous peoples of the Americas among others.
The Infectious Disease Society of America takes the same position as the CDC.

Common adverse drug reactions (ADRs) associated with oseltamivir therapy (occurring in over 1 percent of people) include nausea and vomiting. In adults, oseltamivir increased the risk of nausea for which the number needed to harm was 28 and for vomiting was 22. So, for every 22 adult people on oseltamivir one experienced vomiting. In the treatment of children, oseltamivir also induced vomiting. The number needed to harm was 19. So, for every 19 children on oseltamivir one experienced vomiting. In prevention there were more headaches, kidney, and psychiatric events. Oseltamivir's effect on the heart is unclear: it may reduce cardiac symptoms, but may also induce serious heart rhythm problems.

Postmarketing reports include liver inflammation and elevated liver enzymes, rash, allergic reactions including anaphylaxis, toxic
epidermal necrolysis, abnormal heart rhythms, seizure, confusion, aggravation of diabetes, and haemorrhagic colitis and
Stevens-Johnson syndrome.

The U.S. and EU package inserts for oseltamivir contain a warning of psychiatric effects observed in post-marketing surveillance.
The frequency of these appears to be low and a causative role for oseltamivir has not been established.The 2014 Cochrane review found a dose-response effect on psychiatric events. In trials of prevention in adults one person was harmed for every 94
treated.Neither of the two most cited published treatment trials of oseltamivir reported any drug-attributable serious adverse
events.

It is pregnancy category C in the United States and category B in Australia, meaning that it has been taken by a small number of
women without signs of problems and in animal studies it looks safe. Dose adjustment may be needed in those with kidney problems.

 

 

FAQ

Q1. What's the MOQ?
A: Usually 1 kg. It is based on the different product. Some are 1g and some are 1 ton. Please be free to consult our salesman.

Q2. What's the shipping time?
A: If in stock, we will ship it out immediately. By FeDex will be 3~5 days to you.

Q3. If I need less than the MOQ, is it possible?
A: Yes. Please be free to consult our salesman.

Q4. Can you supply the free sample?
A: Usually it is possible. It based on the different product. Please be free to consult our salesman.

Q5. How to store the product?
A: Store in cool and dry place. It must be in well closed containers.The shelf life will be 2 years.

Q6: What's your main payment method?
A: T/T, Western Union, Money Gram, Paypal.

Q7: Do you have COA, MSDS, CO, Health certificate, form 9 or other certificate?
A: Yes, we have. pls be free to contact us to get updated one